Evoke Pharma Inc (EVOK)
4.33
-0.17
(-3.78%)
USD |
NASDAQ |
Nov 22, 16:00
4.22
-0.11
(-2.54%)
After-Hours: 20:00
Evoke Pharma Cash from Financing (Quarterly): 2.980M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.980M |
| June 30, 2024 | 0.2957M |
| March 31, 2024 | 7.543M |
| December 31, 2023 | -0.1193M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 7.124M |
| March 31, 2022 | 0.1715M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.3131M |
| June 30, 2021 | 0.0455M |
| March 31, 2021 | 13.07M |
| December 31, 2020 | 3.500M |
| September 30, 2020 | 0.1008M |
| June 30, 2020 | 5.413M |
| March 31, 2020 | 0.0213M |
| December 31, 2019 | 0.3067M |
| September 30, 2019 | 0.1238M |
| June 30, 2019 | 5.04M |
| March 31, 2019 | 0.6364M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 1.187M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.887M |
| March 31, 2018 | 0.5446M |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.0569M |
| June 30, 2017 | -0.0025M |
| March 31, 2017 | 7.335M |
| December 31, 2016 | -0.0032M |
| September 30, 2016 | 8.669M |
| June 30, 2016 | 0.2593M |
| March 31, 2016 | 0.0987M |
| December 31, 2015 | 0.4048M |
| September 30, 2015 | 3.360M |
| June 30, 2015 | 0.7349M |
| March 31, 2015 | 0.5316M |
| December 31, 2014 | 4.50M |
| September 30, 2014 | 0.0429M |
| June 30, 2014 | -2.722M |
| March 31, 2014 | -0.3606M |
| December 31, 2013 | 2.348M |
| September 30, 2013 | 22.96M |
| June 30, 2013 | -0.1893M |
| March 31, 2013 | 2.00M |
| December 31, 2012 | 0.00 |
| September 30, 2012 | 1.00M |
| June 30, 2012 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.1193M
Minimum
Dec 2023
13.07M
Maximum
Mar 2021
2.038M
Average
0.1362M
Median
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | 211.30M |
| MEI Pharma Inc | -- |
| Revance Therapeutics Inc | -6.087M |
| NovaBay Pharmaceuticals Inc | 2.089M |
| Palatin Technologies Inc | -0.127M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.8187M |
| Free Cash Flow | -5.325M |
| Free Cash Flow Per Share (Quarterly) | -0.5848 |
| Free Cash Flow to Equity (Quarterly) | -0.8187M |
| Free Cash Flow Yield | -129.5% |